Document is current
Any future updates will be listed below
-
Authors
Sanders, Theodore J. https://orcid.org/0009-0002-9505-8282
Nabel, Christopher S.
Brouwer, Margreet
Hermant, Annelise L.
Chaible, Lucas
Deglasse, Jean-Philippe https://orcid.org/0000-0003-2836-7894
Rosewick, Nicolas
Pabois, Angélique https://orcid.org/0000-0002-1289-1192
Cathou, Wilfried
Smets, Aurore
Deligny, Michael
Marchante, João
Dubray, Quentin https://orcid.org/0009-0006-2261-8129
Letellier, Marie-Claire
Martinoli, Chiara
Marillier, Reece
De Henau, Olivier
McGrath, Yvonne
Vander Heiden, Matthew G. https://orcid.org/0000-0002-6702-4192
Houthuys, Erica https://orcid.org/0009-0001-5476-9486
- License Information
-
More Information
Article History
Received: 19 November 2023
Accepted: 8 April 2025
First Online: 12 May 2025
Competing interests
: T.J.S., M.B., A.L.H., N.R., L.C., J.-P. D., A.P., W.C., A.S., M.D., J.M., Q.D., M.-C.L., C.M., R.M., O.D.H., Y.M. and E.H. are employees of and own stock options and/or shares in iTeos Therapeutics, a company with ownership of EOS301984 described in the paper. M.D. and E.H. are listed as inventors on patent WO/2021/204896 related to EOS301984. C.S.N. acknowledges receiving royalty income from Cambridge Epigenetix and stock ownership in Opko Health. M.G.V.H. is a member of the scientific advisory board for iTeos Therapeutics. M.G.V.H. is also a scientific advisor for Agios Pharmaceuticals, Sage Therapeutics, Auron Therapeutics, Pretzel Therapeutics, Lime Therapeutics, MPM Capital and DROIA Ventures.
